Welcome to our dedicated page for Profound Med news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Med stock.
Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical (NASDAQ:PROF) closed a registered direct offering of 5,142,870 common shares at $7.00 per share for gross proceeds of approximately $36 million before fees and expenses. The offering had no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.
The company said net proceeds will fund sales and marketing expansion, working capital, R&D, strategic transactions and general corporate purposes. Konik Capital Partners acted as exclusive placement agent. The offering was made from an effective Form S-3 shelf declared effective on Dec 4, 2025.
Profound expects to close a related private placement to Canadian purchasers on or before Dec 30, 2025, subject to approvals including conditional Toronto Stock Exchange approval; those securities will not be offered to U.S. persons.
Profound Medical (Nasdaq:PROF) announced a financing package of up to $40 million consisting of a $36 million registered direct offering (5,142,857 common shares at $7.00 per share) and a subsequent Canadian private placement of up to $4 million (571,428 common shares at $7.00 per share).
The registered direct offering is expected to close on or about December 22, 2025, subject to customary conditions; the private placement closing is expected on or prior to December 30, 2025 and is subject to Toronto Stock Exchange conditional approval and a four-month-plus-one-day hold period for those shares.
Gross proceeds to the company are expected to be approximately $36 million before placement agent fees and expenses, and net proceeds are planned for sales and marketing expansion, working capital, R&D, strategic transactions and general corporate purposes.
Profound Medical (NASDAQ:PROF) highlighted RSNA recognition for perioperative data from the CAPTAIN randomized controlled trial comparing MRI-guided TULSA versus robotic radical prostatectomy, presented Dec 4, 2025.
Key points: CAPTAIN successfully recruited to target as a randomized trial; the presentation received an RSNA Cum Laude award (one of six awards, top 5% of posters); reported perioperative data show robotic RP patients take ~three weeks to recover to the same state TULSA patients reach the next day; TULSA has no blood loss and no overnight stay.
Profound Medical (NASDAQ:PROF) will launch the TULSA-AI Volume Reduction module for benign prostatic hyperplasia (BPH) at RSNA, Nov 30–Dec 4, 2025, and present new TULSA-PRO clinical data at RSNA and SUO (Dec 2–5, 2025).
The AI-powered module is described as optimizing BPH treatment workflow, reducing procedure times, and enabling multiple same-day cases with existing hardware and reimbursement codes. Company cites pilot trial success, CAPTAIN perioperative data comparing TULSA favorably to robotic prostatectomy on blood loss, length of stay, post-op pain and recovery, and projects a total available prostate-disease market of ~600,000 patients annually.
Profound Medical (NASDAQ:PROF) announced that The Hong Center Scottsdale, led by Dr. Y. Mark Hong, reached a world-first milestone of 200 independent TULSA Procedures performed by a urologist without radiologist involvement on Nov 18, 2025. The milestone highlights a urology-led, MRI-guided, incision-free workflow using the TULSA-PRO system, which offers real-time MRI thermography, autonomous temperature control, and robotically controlled directional ultrasound to ablate prostate tissue while protecting nearby structures.
The announcement notes consistent high-volume experience across whole-gland, focal, BPH and salvage cases, with no procedural blood loss or hospitalization reported and an emphasis on preserved urinary and sexual function.
Profound Medical (NASDAQ:PROF) reported record Q3 2025 revenue of $5.3M, up 87% YoY, driven by $4.1M recurring non-capital revenue and $1.2M capital equipment sales. Gross margin expanded 1,119 bps to 74.3% on manufacturing efficiency. Installed base reached 70 systems with a qualified pipeline of 93 new systems; the company expects at least 75 installs by year-end. Q3 net loss improved to $8.0M ($0.26/share) from $9.4M a year ago. Cash was approximately $24.8M as of September 30, 2025. The company announced new distribution agreements and clinical program milestones to support adoption.
Profound Medical (NASDAQ:PROF) announced an exclusive distribution and supply agreement with Getz Healthcare to commercialize the TULSA-PRO system in Australia and New Zealand, dated November 12, 2025. TULSA-PRO is an AI-powered, MRI-guided, robotically controlled system for prostate ablation that enables real-time MRI thermography and autonomous temperature control.
The partnership aims to expand access to incision-free prostate therapy in Australasia while Profound continues direct sales in North America and seeks further APAC distribution opportunities with Getz Healthcare.
Profound Medical (NASDAQ:PROF) announced an exclusive distribution and supply agreement with Al Faisaliah Medical Systems for its incision-free, MRI-guided TULSA-PRO and Sonalleve technologies in Saudi Arabia on Nov 11, 2025. All required import and sales regulatory approvals for Saudi Arabia are in place. TULSA-PRO has an installed base of 67 systems (Oct 2025) and >4,000 men treated; Sonalleve has 10 devices operational globally and >4,000 women treated for uterine conditions. The deal targets the Kingdom’s large healthcare market and leverages FMS’s regional distribution capabilities.
Profound Medical (NASDAQ:PROF) regained exclusive Canadian distribution rights for the TULSA-PRO system from Knight effective Nov 10, 2025, in exchange for a one-time payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian Net Sales for 15 years. Currently only Sunnybrook Health Sciences Centre in Toronto offers the TULSA Procedure and has performed >100 procedures. Profound plans to deploy its North American direct sales team, pursue additional Canadian sites through a concierge model, and use upcoming CAPTAIN trial results (readouts starting 2026) to support provincial coverage applications.
Profound Medical (NASDAQ:PROF) announced real-world data from the Busch Center marking its 500th TULSA Procedure on Oct 16, 2025. The center reported a mix of indications: ~50% primary prostate cancer, ~33% BPH, and remaining salvage cases.
Key outcomes include whole-gland ablations covering >90% of prostate in >75% of cases, treatment volumes up to 250 cc, >15% high-risk cancers treated, and a retrospective PSA fall from 6.7 to 0.9 ng/mL with 93% no residual disease. Reported functional outcomes: 100% pad-free continence and 82% preserved erectile function in the analyzed cohort.